Protective effects of Ginkgo Biloba Dropping Pills against liver ischemia/reperfusion injury in mice

Zheng Wang, Ping Zhang, Qingqing Wang, Xueping Sheng, Jianbing Zhang, Xiaoyan Lu, Xiaohui FanChinese 2020 · DOI

TL;DR

This study investigates the protective effects of Ginkgo Biloba Dropping Pills (GBDP) against liver ischemia/reperfusion (I/R) injury, a critical complication in liver transplantation and surgery. Researchers found that GBDP significantly reduces liver cell damage, apoptosis, and inflammation in both cell culture and mouse models, suggesting its potential as a therapeutic agent for I/R injury.

What Problem Does This Paper Address?

Liver ischemia/reperfusion (I/R) injury is a major cause of morbidity and mortality following liver transplantation, resection surgery, or shock. This injury occurs when blood flow to the liver is interrupted (ischemia) and then restored (reperfusion), leading to a complex cascade of cellular damage. The initial ischemia causes hepatocytes to dysfunction due to lack of oxygen. Upon reperfusion, the sudden influx of oxygen generates reactive oxygen species (ROS), which further exacerbate cellular damage. This process results in hepatocyte necrosis, apoptosis (programmed cell death), and a significant inflammatory response, all contributing to graft failure and poor patient outcomes. While research has identified mechanisms involved, clinically effective interventions to prevent or treat I/R injury remain limited. This paper aims to explore the therapeutic potential of Ginkgo Biloba Dropping Pills (GBDP), a traditional Chinese medicine preparation, in mitigating this damage.

Methods

The study employed a two-pronged approach, utilizing both in vitro and in vivo models:

  • In Vitro Studies:
    • Hypoxia/Reoxygenation (H/R) Model: Alpha mouse liver 12 (AML-12) cells and primary hepatocytes were subjected to H/R conditions to mimic I/R injury.
  • Cell Viability Assay: The MTT assay was used to quantify cell survival after H/R injury, with and without GBDP pretreatment.
  • Apoptosis Detection: Annexin V staining was performed to identify and quantify apoptotic cells. Western blot analysis was used to assess the expression levels of key apoptosis-related proteins (Bax, Bcl-2, PARP-1, and caspase-3).
  • In Vivo Studies:
    • Liver I/R Injury Model: A standard liver I/R injury model was established in C57BL/6 mice.
  • Drug Treatment: Mice were pretreated with GBDP (100 or 200 mg/kg/day) via gavage for two weeks prior to the I/R procedure.
  • Liver Damage Assessment: Plasma levels of alanine transaminase (ALT) and aspartate transaminase (AST), markers of liver damage, were measured. Histopathological examination using Hematoxylin and Eosin (H&E) staining was conducted to assess liver necrosis.
  • Inflammation Assessment: Myeloperoxidase (MPO) immunohistochemistry was used to quantify neutrophil infiltration. Enzyme-linked immunosorbent assay (ELISA) was employed to measure the levels of pro-inflammatory cytokines (IL-6 and MCP-1).
  • Apoptosis Assessment: Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick and labeling (TUNEL) staining was used to detect apoptotic cells in liver tissue. Western blot analysis was performed to examine the expression of apoptosis-related proteins.

Datasets

Not discussed in the paper. The study utilized established cell lines (AML-12) and primary cells isolated from mice, as well as a standard animal model.

Key Insights and Ideas

  • GBDP as a Multifaceted Protector: The study reveals that GBDP doesn't just target one aspect of I/R injury; it exhibits a broad protective effect by simultaneously combating apoptosis, necrosis, and inflammation. This suggests a comprehensive therapeutic mechanism.
  • Translational Potential: The successful demonstration of GBDP's efficacy in both in vitro cell models and in vivo animal models strengthens its potential for clinical application in treating liver I/R injury.
  • Dose-Dependent Effects: The observed improvements in cell viability and reductions in injury markers were often dose-dependent, indicating that higher concentrations of GBDP provided greater protection.
  • Mechanism of Action: The study points towards GBDP's ability to modulate key apoptotic pathways (e.g., Bax, Bcl-2, PARP-1, caspase-3) and reduce inflammatory mediators (IL-6, MCP-1), providing a molecular basis for its protective effects.

Key Results

  • In Vitro: GBDP pretreatment significantly improved the viability of AML-12 cells and primary hepatocytes subjected to H/R injury. It also dose-dependently reduced the number of apoptotic cells and downregulated the expression of pro-apoptotic proteins (Bax, PARP-1, caspase-3) while upregulating anti-apoptotic protein (Bcl-2).
  • In Vivo: Oral administration of GBDP significantly reduced elevated plasma ALT and AST levels, indicating decreased liver damage. H&E staining showed a reduction in liver necrosis. MPO staining and ELISA results demonstrated that GBDP inhibited neutrophil infiltration and the secretion of pro-inflammatory cytokines (IL-6, MCP-1). Furthermore, TUNEL staining and western blot analysis confirmed that GBDP attenuated hepatocellular apoptosis in the liver by modulating apoptosis-related protein expression.

Limitations and Future Work

  • Specific Components: While GBDP is a preparation of Ginkgo Biloba leaf extract, the study does not delve into identifying the specific active components within GBDP responsible for the observed protective effects. Future work could focus on isolating and characterizing these compounds.
  • Detailed Mechanisms: Although key apoptotic and inflammatory pathways were investigated, a more in-depth exploration of the precise molecular mechanisms by which GBDP exerts its effects could be beneficial. This might include investigating signaling pathways beyond those directly measured.
  • Long-Term Effects and Safety: The study focused on acute I/R injury. Further research could explore the long-term effects of GBDP administration and its safety profile in chronic or repeated I/R scenarios.
  • Human Trials: The ultimate validation of GBDP's therapeutic potential would require well-designed clinical trials in human patients undergoing procedures at risk of liver I/R injury.

Summary updated

Abstract

Our findings elucidated that GBDP has potential effects for protecting against liver I/R injury characterized by its anti-apoptotic, anti-necrotic, and anti-inflammatory properties, which would promisingly make contributions to the exploration of therapeutic strategies in the liver I/R injury.
BibTeX
@inproceedings{wang2020protective,
  author = {Zheng Wang and Ping Zhang and Qingqing Wang and Xueping Sheng and Jianbing Zhang and Xiaoyan Lu and Xiaohui Fan},
  title = {{Protective effects of Ginkgo Biloba Dropping Pills against liver ischemia/reperfusion injury in mice}},
  booktitle = {Chinese},
  year = {2020},
  doi = {10.1186/s13020-020-00404-z},
}
Figure